Oncology News Saladax Biomedical Welcomes New Guidelines from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) for 5-Fluorouracil Therapy Bethlehem, PA – September 19, 2018 – Saladax Biomedical Inc., a diagnostics company providing kits…John BuckleySeptember 19, 2018
Psychiatry News Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc., a diagnostics company providing kits to measure drug blood levels…John BuckleyJune 26, 2018
Psychiatry News Saladax Receives Approval to Sell a New Line of Psychiatry Tests on the European Market Saladax is Advancing Personalized Medicine by Providing Doctors with Tests for Drug Levels to Better…John BuckleyMarch 21, 2018
General NewsOncology News Saladax is Awarded “Best Poster Presentation” for Study on Individualized Dosing of Paclitaxel Saladax Biomedical, Inc., recently presented a study on the value of adjusting paclitaxel doses. The…John BuckleyOctober 14, 2017
Psychiatry News Saladax Licenses Alzheimer’s Diagnostic Tests to Siemens Healthineers Tests can lead to early identification of Alzheimer’s Disease Bethlehem, PA--(BUSINESS WIRE)--January 18, 2017-- Saladax…John BuckleyJanuary 18, 2017
General News Salvatore J. Salamone, Ph.D., Founder and CEO of Saladax Biomedical, Inc. Inducted into the New Jersey Inventors Hall of Fame Saladax Biomedical, Inc., the leader in developing oncology diagnostics that increase the impact of personalized…John BuckleyOctober 28, 2016
Oncology News Study Shows That Therapeutic Drug Monitoring Can Reduce Paclitaxel-Associated Neuropathy Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced…John BuckleyOctober 19, 2016
Oncology News Saladax Biomedical, Inc. Announces Presentation of CEPAC-TDM Study of Paclitaxel in Non-Small Cell Lung Cancer at 2015 ASCO Meeting Large Study Confirms the Benefit to Patients of Advanced Dosing Method Saladax Biomedical, Inc. recently…John BuckleyJune 9, 2015
Oncology News Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting Advantages of a Practical Approach to Personalized Dosing of 5-FU Demonstrated Saladax Biomedical, Inc. recently…John BuckleyJune 8, 2015
Oncology News Personalized Chemotherapy Tests Cleared for Use in China Exposure Optimization Tests Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today…John BuckleyJuly 23, 2014